Perkin-Elmer Eyes the Value Chain
Perkin-Elmer built the machines that enabled the boom in genomics research--automated DNA sequencers. Genomics companies have done well, but Perkin-Elmer hasn't. The company is prepared to spend up to $1 billion over the next several years on external collaborations and acquisitions in an effort to climb the value chain and capture high-value applications of its tools for itself.
You may also be interested in...
As it announced the formal European Commission approval of its partnered Polpharma Biologics-developed Tyruko natalizumab biosimilar to Tysabri, Sandoz offered Generics Bulletin a timeframe for its expected launch in Europe.
Cytokinetics has a lot riding on the upcoming Phase III readout for aficamten, and crunch time is coming for plenty of other groups, too.
Biotech has always been a volatile sector, and it is important for investors to recognize the phases its stocks go through. In particular, the journey through the post-bubble wilderness can be a protracted affair.